Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ringash, Jolie
  • Waldron, John N
  • Siu, Lillian L
  • Martino, Rosemary
  • Winquist, Eric
  • Wright, James
  • Nabid, Abdenour
  • Hay, John H
  • Hammond, Alex
  • Sultanem, Khalil
  • Hotte, Sebastien
  • Leong, Carson
  • El-Gayed, Ali Abdel Halim
  • Naz, Farah
  • Ramchandar, Kevin
  • Owen, Tim E
  • Montenegro, Alexander
  • O'Sullivan, Brian
  • Chen, Bingshu E
  • Parulekar, Wendy R

publication date

  • May 20, 2015